Further, we also observed a trend where the non-MYCN-amplified tumors had higher GSK-3β expression compared to MYCN-amplified tumors in the Versteeg cohort, however this difference did not reach statistical significance (Fig.
← all excerpts
Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells.
1
—
—